Jan : Delaval

Access DB# 53605

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabiha (STIC) Qazi Examiner #: 74141 Date: 10/23/01

Art Unit: 1616 Phone Number 30 5-3910 Serial Number: 09/497,891

Mail Box and Bldg/Room Location: 2019 Results Format Preferred (circle): PAPER DISK E-MAIL

Off. 3B07

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: 16 - Hydroxyestratrienes as Selectively Active Estrogens

Inventors (please provide full names): HERMAN KUENZER et al

Earliest Priority Filing Date: 2/4/00

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Pl. search for the Compds of Cl. 1, elected Species contain no double bond in Rings C, D & E.

First search elected species, and then expand the search if necessary.

Thank you.

Point of Contact:
Jan Delaval
Librarian-Physical Sciences
CM1 1E04 Tel: 308-4498

Pl. see attached sheets.

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher:		NA Sequence (#)		STN ✓
Searcher Phone #:	4465	AA Sequence (#)		Dialog
Searcher Location:		Structure (#)	3	Questel/Orbit
Date Searcher Picked Up:		Bibliographic		Dr.Link
Date Completed:	10/31/01	Litigation		Lexis/Nexis
Searcher Prep & Review Time:		Fulltext		Sequence Systems
Clerical Prep Time:		Patent Family		WWW/Internet
Online Time:	1.0	Other		Other (specify)

PTO-1590 (8-01)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 13:19:22 ON 31 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   29 OCT 2001  HIGHEST RN 365398-80-7
DICTIONARY FILE UPDATES:  29 OCT 2001  HIGHEST RN 365398-80-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER see
HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l40
```

L29 STR




```
VAR G1=X/OH/AK/32/23/H
VAR G2=X/OH/AK/23/H
VAR G4=X/AK/32/26/23/H
VAR G8=H/AK/43/45/32/38/49/CN
VAR G9=H/AK/32/26
VAR G13=AK/32/26
VAR G16=AK/43/45/32/38/49/55/H
VAR G17=X/AK/43/45/32/38/49/H/OH
NODE ATTRIBUTES:
CONNECT IS M1  RC AT   9
CONNECT IS M1  RC AT  10
CONNECT IS M1  RC AT  13
CONNECT IS M1  RC AT  17
CONNECT IS M1  RC AT  38
CONNECT IS M1  RC AT  49
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 57

STEREO ATTRIBUTES: NONE
L31 425 SEA FILE=REGISTRY CSS FUL L29
L32 STR



Page 1-A



Page 2-A
VAR G1=X/OH/AK/32/23/H
VAR G2=X/OH/AK/23/H
VAR G4=X/AK/32/26/23/H
VAR G7=X/AK/43/45/32/38/49/23/H/60
VAR G8=H/AK/43/45/32/38/49/CN
VAR G9=H/AK/32/26
VAR G11=62/OH/S/X/43/45/32/38/49/AK/23/64/60/H
VAR G13=AK/32/26
VAR G16=AK/43/45/32/38/49/55/H
VAR G17=X/AK/43/45/32/38/49/H/OH
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 13
CONNECT IS M1 RC AT 17
CONNECT IS M1 RC AT 38

```
CONNECT IS M1  RC AT  49
CONNECT IS M1  RC AT  60
CONNECT IS M1  RC AT  63
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  64

STEREO ATTRIBUTES: NONE
L33         400 SEA FILE=REGISTRY SUB=L31 CSS FUL L32
L34          12 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 AND C3-C5-C6-C6-C6/ES
L35         388 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 NOT L34
L36             STR
```







Page 1-A



Page 2-A

```
VAR G1=X/OH/AK/32/23/H
VAR G2=X/OH/AK/23/H
VAR G4=X/AK/32/26/23/H
VAR G7=X/AK/43/45/32/38/49/23/H/60
VAR G8=H/AK/43/45/32/38/49/CN
VAR G9=H/AK/32/26
VAR G11=62/OH/S/X/43/45/32/38/49/AK/23/64/60/H
```

```
VAR G13=AK/32/26
VAR G14=AK/43/45/32/38/49/H
VAR G16=AK/43/45/32/38/49/55/H
VAR G17=X/AK/43/45/32/38/49/H/OH
NODE ATTRIBUTES:
CONNECT IS M1  RC AT  17
CONNECT IS M1  RC AT  38
CONNECT IS M1  RC AT  49
CONNECT IS M1  RC AT  60
CONNECT IS M1  RC AT  63
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  65

STEREO ATTRIBUTES: NONE
L37         385 SEA FILE=REGISTRY SUB=L35 CSS FUL L36
L38           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L35 NOT L37
L39           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND C18H22O3
L40         398 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L34 OR L37 OR L39)


=> d his l41

     (FILE 'REGISTRY' ENTERED AT 12:28:45 ON 31 OCT 2001)
               SAV L40 TEMP QAZI497C/A

     FILE 'REGISTRY' ENTERED AT 13:19:22 ON 31 OCT 2001
L41            8 S L40 AND C20H28O2

=> d scan l41

L41  8 ANSWERS   REGISTRY  COPYRIGHT 2001 ACS
IN   Estra-1,3,5(10)-triene-3,16-diol, 15-ethyl-, (15.alpha.,16.alpha.)- (9CI)
MF   C20 H28 O2

Absolute stereochemistry.
```



retrieval of species based on MF + structure - cmpd not found

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L41  8 ANSWERS   REGISTRY  COPYRIGHT 2001 ACS
IN   Estra-1,3,5(10)-triene-3,16-diol, 15-ethyl-, (15.beta.,16.beta.)- (9CI)
MF   C20 H28 O2

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L41 8 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 7-ethyl-, (7.alpha.,16.beta.)- (9CI)
MF **C20 H28 O2**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L41 8 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 15-ethyl-, (15.alpha.,16.beta.)- (9CI)
MF **C20 H28 O2**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L41 8 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 7-ethyl-, (7.alpha.,16.alpha.)- (9CI)
MF **C20 H28 O2**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L41 8 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 7-ethyl-, (7.beta.,16.beta.)- (9CI)
MF **C20 H28 O2**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L41 8 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 15-ethyl-, (15.beta.,16.alpha.)- (9CI)
MF **C20 H28 O2**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L41 8 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 7-ethyl-, (7.beta.,16.alpha.)- (9CI)
MF **C20 H28 O2**

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d ide can tot

L51 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2001 ACS
RN 109581-80-8 REGISTRY
CN **1,3,5(10),7-Estratetraene-3,16.beta.-diol (6CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF **C18 H22 O2**
SR CAOLD
LC STN Files: CAOLD

Absolute stereochemistry.



1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L51 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2001 ACS
RN 109396-95-4 REGISTRY
CN **1,3,5(10),7-Estratetraene-3,16.alpha.-diol (6CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF **C18 H22 O2**
SR CAOLD
LC STN Files: CAOLD

Absolute stereochemistry.



1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L51 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2001 ACS
RN 1225-58-7 REGISTRY
CN **Estra-1,3,5(10)-triene-3,16-diol, (16.beta.)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-3,16.beta.-diol (6CI, 7CI, 8CI)
OTHER NAMES:
CN 16.beta.-Estradiol
CN 3,16.beta.-Dihydroxyestra-1,3,5,(10)-triene
FS STEREOSEARCH
MF C18 H24 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CSCHEM, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)
12 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:150782

REFERENCE 2: 112:801

REFERENCE 3: 109:222771

REFERENCE 4: 106:96443

REFERENCE 5: 106:16187

REFERENCE 6: 103:174487

REFERENCE 7: 100:47664

REFERENCE 8: 95:161659

REFERENCE 9: 88:116912

REFERENCE 10: 79:105459

L51 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2001 ACS
RN 1090-04-6 REGISTRY
CN **Estra-1,3,5(10)-triene-3,16-diol, (16.alpha.)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-3,16.alpha.-diol (6CI, 7CI, 8CI)
OTHER NAMES:
CN 16.alpha.-Estradiol
CN 17-Deoxyestriol
CN NSC 24550

FS STEREOSEARCH
MF C18 H24 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CSCHEM, MEDLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

45 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
45 REFERENCES IN FILE CAPLUS (1967 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:261332

REFERENCE 2: 134:80974

REFERENCE 3: 131:332226

REFERENCE 4: 131:223634

REFERENCE 5: 127:288310

REFERENCE 6: 123:306774

REFERENCE 7: 123:48115

REFERENCE 8: 122:306705

REFERENCE 9: 120:261630

REFERENCE 10: 119:262769

=> d ide can tot 134

L34 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287723-53-9 REGISTRY
CN Cyclopropa[14,15]gona-1,3,5(10)-triene-3,16-diol, 13-ethyl-3',15-dihydro-7-phenyl-, (7.alpha.,14R,15.beta.,16.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H30 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 2 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287723-43-7 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-7-phenyl-, (7.alpha.,14S,15.alpha.,16.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H28 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



example 07
R14 - R15 = methylene + structure search

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287723-42-6 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-7-phe
(7.alpha.,14R,15.beta.,16.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H28 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287723-37-9 REGISTRY
CN Cyclopropa[14,15]gona-1,3,5(10)-triene-3,16-diol, 13-ethyl-3',15-dihydro-7-phenyl-, (7.alpha.,14R,15.beta.,16.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H30 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287723-24-4 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-7-phenyl-, (7.alpha.,14S,15.alpha.,16.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H28 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 6 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287723-23-3 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-7-phenyl-, (7.alpha.,14R,15.beta.,16.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H28 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 7 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287721-90-8 REGISTRY
CN Cyclopropa[14,15]gona-1,3,5(10)-triene-3,16-diol, 13-ethyl-3',15-dihydro-, (14R,15.beta.,16.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H26 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287721-81-7 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-, (14S,15.alpha.,16.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H24 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287721-80-6 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-, (14R,15.beta.,16.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H24 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287721-77-1 REGISTRY
CN Cyclopropa[14,15]gona-1,3,5(10)-triene-3,16-diol, 13-ethyl-3',15-dihydro-, (14R,15.beta.,16.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H26 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287721-67-9 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-, (14S,15.alpha.,16.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H24 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

L34 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2001 ACS
RN 287721-66-8 REGISTRY
CN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-, (14R,15.beta.,16.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H24 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:150782

=> d his

(FILE 'HOME' ENTERED AT 12:22:57 ON 31 OCT 2001)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:23:08 ON 31 OCT 2001
L1 229680 S C5-C6-C6-C6/ES
L2 538 S L1 AND C20H28O2
L3 526 S L2 AND 1/NC

FILE 'HCAPLUS' ENTERED AT 12:24:46 ON 31 OCT 2001
E FRITZEMEIER K/AU
L4 60 S E4-E8
E KUENZER H/AU
L5 50 S E3,E5

```
                E KUNZER H/AU
L6          10 S E3,E4
                E KNAUTHE R/AU
L7          13 S E3,E5
                E LESSL M/AU
L8          23 S E3,E4
                E HEGELE/AU
L9          51 S E8-E10
                E HARTUNG/AU
L10         13 S E3,E16
                E BOEMER U/AU
L11          6 S E4
                E BOMER U/AU
L12          7 S E4
                E MUELLER G/AU
L13       1016 S E3-E22
L14        148 S E64-E67
                E MULLER G/AU
L15        463 S E3-E17,E36-E39
                E KOSEMUND D/AU
L16          7 S E3,E4
                E DE99-19906159/AP,PRN
L17          1 S E3,E4
L18          1 S L17 AND L4-L16
L19         87 S STEROID?/SC,SX,CW AND L4-L16
L20         86 S L19 NOT L18
                SEL RN L18

    FILE 'REGISTRY' ENTERED AT 12:28:45 ON 31 OCT 2001
L21        289 S E1-E289
L22         10 S L21 AND L2
L23        491 S 4432.3/RID AND L2
L24        144 S L23 AND 4432.3.65/RID
L25         13 S L24 AND 13 ETHYL
L26          3 S L25 NOT METHOXY
L27         24 S L23 AND 13 ETHYL NOT METHOXY
L28         21 S L27 NOT L25
L29            STR
L30         12 S L29 CSS
L31        425 S L29 CSS FUL
                SAV TEMP L31 QAZI497/A
L32            STR L29
L33        400 S L32 CSS FUL SUB=L31
                SAV TEMP L33 QAZI497A/A
L34         12 S L33 AND C3-C5-C6-C6-C6/ES
L35        388 S L33 NOT L34
L36            STR L32
L37        385 S L36 CSS FUL SUB=L35
                SAV L37 QAZI497B/A
L38          3 S L35 NOT L37
L39          1 S L38 AND C18H22O3
L40        398 S L34,L37,L39
                SAV L40 TEMP QAZI497C/A

    FILE 'REGISTRY' ENTERED AT 13:19:22 ON 31 OCT 2001
L41          8 S L40 AND C20H28O2

    FILE 'HCAPLUS' ENTERED AT 13:20:08 ON 31 OCT 2001
L42       4261 S L40
L43          4 S L42 AND L4-L18

    FILE 'REGISTRY' ENTERED AT 13:21:16 ON 31 OCT 2001
L44          1 S ESTRIOL/CN
               E ESTRA-1,3,5(10)-TRIENE-3,16/CN
               E ESTRA-1,3,5(10)-TRIENE-3,16-DIOL/CN
L45          2 S E4,E5
```

```
                E ESTRA-1,3,5(10),7-TETRAENE-3,16-DIOL/CN
                E ESTRA-1,3,5(10),7-TETRAEN/CN
                E ESTRA-1,3,5(10),7-TETRAENE/CN
L46           1 S E28
                E RSD
L47         245 S 4432.3.177/RID
L48          15 S C18H22O2 AND L47
L49           4 S L48 AND 16
L50           2 S L49 NOT D/ELS
L51           4 S L45,L50
L52         395 S L40 NOT L44,L51

     FILE 'HCAPLUS' ENTERED AT 13:30:49 ON 31 OCT 2001
L53         654 S L52
L54         628 S L53 AND (PD<=19990427 OR PRD<=19990427 OR AD<=19990427)
L55           1 S L4-L18 AND L53
                E ESTROGEN/CW
L56       34431 S E3-E5
                E ESTROGEN/CT
                E E5+ALL
L57         130 S E1
                E E2+ALL
L58         271 S E7
                E E6+ALL
L59       33010 S E6,E7,E21-E25
L60        6077 S E27+NT
L61        1703 S E28+NT
L62       36014 S E29+NT
                E E27+ALL
L63        6728 S E14
                E OVARY/CT
                E E3+ALL
L64       37307 S E7,E6+NT
L65       24849 S E17+NT
L66        8203 S E20+NT
                E E19+ALL
L67        8806 S E4,E3+NT
L68         953 S E13+NT
                E E12+ALL
L69        1703 S E4+NT
                E E10+ALL
L70        5444 S E5,E4+NT
L71         273 S L54 AND L56-L70
                E OSTEOPOR/CT
                E E4+ALL
L72        6222 S E6+NT
                E BONE DENSITY/CT
L73         743 S E4
L74         268 S E2
L75           6 S L54 AND L72-L74
L76          30 S L71 AND P/DT
L77          33 S L75,L76
L78           1 S L77 AND L55
L79          32 S L77 NOT L78
                SEL HIT RN L79

     FILE 'REGISTRY' ENTERED AT 13:38:36 ON 31 OCT 2001
L80          26 S E1-E26

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:41:35 ON 31 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1947 - 31 Oct 2001 VOL 135 ISS 19
FILE LAST UPDATED: 30 Oct 2001 (20011030/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d bib abs hitstr tot

L81 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:738805 HCAPLUS
DN 133:296594
TI Preparation of ent-steroids as selectively effective estrogens
PA Schering A.-G., Germany
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19917930	A1	20001019	DE 1999-19917930	19990415 <--
	WO 2000063228	A1	20001026	WO 2000-EP3470	20000417 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI DE 1999-19917930 A 19990415 <--
OS MARPAT 133:296594
GI



I

patent reference
Some hits include multicomponent cmpds which I did not eliminate

AB The invention describes new ent-steroids I [R1 = H, OR12, alkenyloxy, alkynyloxy, OSO2R13; R2 = OR12, OSO2R13, OC(:O)R16; R3, R4, R5, R8, R9 = H, halogen, OR12, OSO2R13, R16 ; R6 = .beta.-H; R7 = H; R6R7 = .alpha.-, .beta.-CH2; R10 = H2, dihalogen, H and a halogen, :CR17R18; R11 = H, Me, Et; R12 = H, C1-5-alkyl, C1-5-alkenyl; R13 = , NR14R15; R14, R15 = H, C1-5-alkyl, COR16, C3-7-cycloalky, aryl; R14R15 = polymethylene; NR14R15 = morpholine; R16 = C1-12-alkyl, C1-12-alkenyl, C1-12-alkynyl; R17, R18 = H, halogen, H and OR12, H and OSO2R13, R12 and OC(:O)R16, O; one or more double bonds at C(6)-C(7), C(7)-C(8), C(8)-C(9), C(9)-C(11), C(11)-C(12), C(8)-C(14), C(14)-C(15), C(15)-C(16), C(16)-C(17)], as pharmaceutically active substances, which exhibit in vitro a higher affinity at estrogen receptor of rat prostate than at estrogen receptor of Rat uterus and in vivo a preferential effect at the bone in the comparison to the uterus, their prodn., its therapeutic application and pharmaceutical compns., which contain the new compds. Thus, ent-estriol (I; R1 = R3 = R4 = R5 = R6 = R7 = R8 = H, R2 = OH, R9 = .alpha.-OH, R10 = .beta.-OH, R11 = Me) was prepd. stereoselectively from ent-3,16.alpha.-dihydroxyestra-1,3,5(10)-trien-17-one (I; R1 = R3 = R4 = R5 = R6 = R7 = R8 = H, R2 = OH, R9 = .alpha.-OH, R10 = O, R11 = Me) via redn. with NaBH4 in MeOH. Furthermore the invention describes the use of steroids, those with the (8.alpha.-H,9.beta.-H,10.alpha.-H,13.alpha.-H,14.beta.-H)-gonane skeleton, for the treatment of estrogen deficiency conditioned diseases and conditions.

IT **300853-07-0P**, ent-Estriol **300853-08-1P**, ent-Estra-1,3,5(10)-triene-3,16.alpha.-diol
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of ent-steroids as selectively effective estrogens)

RN 300853-07-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, (8.alpha.,9.beta.,13.alpha.,14.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300853-08-1 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16-diol, (8.alpha.,9.beta.,13.alpha.,14.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2001 ACS

AN 2000:316824 HCAPLUS
DN 132:325393
TI Separating agents, separation of estrogens and environmental estrogens, and screening and adsorptive removal of environmental estrogens
IN Haginaka, Atsushi; Sanbe, Haruyo
PA Mitsubishi Chemical Industries Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2000135435	A2	20000516	JP 1999-206029	19990721 <--
PRAI JP 1998-239934		19980826 <--		

AB The sepg. agents comprise macromol. particles having template structure against estrogens and environmental estrogens and are used for sepn. of environmental estrogens by reversed phase HPLC using the sepg. agents as the solid phase. Screening of environmental estrogens by comparing the sepn. behavior of estrogens and environmental estrogens in reversed phase HPLC and adsorptive removal of environmental estrogens with the sepg. agents are also claimed. Estrogens and environmental estrogens are effectively sepd.
IT **547-81-9**, 16-Epiestriol
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(sepn. of environmental estrogens from; sepn. of estrogens and environmental estrogens with template-structured sepg. agents by reversed phase HPLC)
RN 547-81-9 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:65480 HCAPLUS
DN 132:113095
TI Locally applicable pharmaceutical preparations for prophylaxis and therapy of atrophic features in the oral cavity
IN Druckmann, Rene; Graeser, Thomas; Fricke, Sabine
PA Jenapharm G.m.b.H. & Co. K.-G., Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT **Patent**
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19832169	A1	20000127	DE 1998-19832169	19980717 <--
WO 2000003719	A1	20000127	WO 1999-EP5075	19990716 <--

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU,

ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9951606 A1 20000207 AU 1999-51606 19990716 <--
PRAI DE 1998-19832169 A 19980717 <--
WO 1999-EP5075 W 19990716
AB Periodontal and other oral diseases are treated locally with adherent creams or gels or with lingual, sublingual, periodontal, or buccal prepns. contg. estrogens to prevent or postpone age-related parodontosis, periodontal atrophy, and receding gums. Thus, a gel contained micronized estriol 0.10, poly(acrylic acid) 1.00, 10% NaOH soln. .apprx.2, 96% EtOH 10.00, SDS 0.50, propylene glycol 10.00, and H2O to 100.00 g.
IT **162707-58-6**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(locally applicable pharmaceutical prepns. for prophylaxis and therapy of atrophic features in the oral cavity)
RN 162707-58-6 HCAPLUS
CN Estra-1,3,5(10),6-tetraene-3,16,17-triol, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1
RE
(1) Anon; DE 19646392 HCAPLUS

L81 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:375692 HCAPLUS
DN 131:27944
TI Method for identifying agonists and antagonists of DNA replication using an in vitro mammalian DNA replication system
IN Wainer, Irving W.; Diaz-Perez, Maria; Azzaoui, Kamal; Zannis-Hadjopoulos, Maria; Price, Gerald B.
PA McGill University, Can.
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9928496	A1	19990610	WO 1998-CA1109	19981130 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9914770 A1 19990616 AU 1999-14770 19981130 <--
PRAI CA 1997-2223216 19971201 <--

WO 1998-CA1109 19981130 <--

AB The present invention relates to an in vitro mammalian DNA replication system and to a method for identifying agonists and antagonists of DNA replication. The method comprises contacting in vitro a plasmid with a mixt. comprising nuclear or cytoplasmic exts. from HeLa cells, the drug and a mixt. of nucleotides, assessing the stimulation or the inhibition of initiation of DNA replication and the elongation of nascent DNA produced by the drug, and identifying the essential structures of the drug by quant. structure-activity relationship (QSAR) anal. deriving relationships between the structural features of the drug and biol. responses produced by the binding of the drug to the target receptor. The plasmid has a target receptor and comprises a specific mammalian origin of DNA replication. The invention demonstrated that steroids can directly affect the DNA replication in the above in vitro system which is lacks of 17.beta.-estradiol and progesterone receptors.

IT **547-81-9**, 16-Epiestriol **793-89-5**, 16,17-Epiestriol
1228-72-4, 17-Epiestriol
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(method for identifying agonists and antagonists of DNA replication using in vitro mammalian DNA replication system)

RN 547-81-9 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 793-89-5 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1228-72-4 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5
RE
(1) Azzaoui; Abstracts of Papers of the American Chemical Society 1997, V214(1), P109
(2) Azzaoui; J Med Chem 1998, V41, P1392 HCAPLUS
(3) Diaz-Perez; J Cell Biochem 1996, V61, P444 HCAPLUS
(4) King, R; Applied Artificial Intelligence 1995, V9(2), P213
(5) Zannis-Hadjopoulos; Gene 1994, V151, P273 HCAPLUS

L81 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:139865 HCAPLUS
DN 130:205114
TI Transition metal and lewis acid complexes with steroid-receptor binding agents, in particular catechol estrogens, preparation, and therapeutic use
IN Humphries, Walter Robson
PA Rowett Research Services Limited, UK
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9909050	A1	19990225	WO 1998-GB2435	19980813 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9887409	A1	19990308	AU 1998-87409	19980813 <--
PRAI	GB 1997-17041		19970813 <--		
	WO 1998-GB2435		19980813 <--		

AB Steroidal antagonists or agonists being complexes formed from (i) a transition metal or a non-transition metal Lewis acid and (ii) a receptor binding ligand capable of binding to a steroid receptor. The compds. may be used in the prevention and treatment of steroid-dependent disorders, e.g. tumors.
IT **1232-80-0D**, complexes
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transition metal and lewis acid complexes with steroid-receptor binding agents, in particular catechol estrogens, prepn., and therapeutic use)
RN 1232-80-0 HCAPLUS
CN Estra-1,3,5(10)-triene-2,3,16,17-tetrol, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8
RE
(1) Beattie, J; Journal of Inorganic Biochemistry 1992, V46(3), P153 HCAPLUS
(2) Gelbke, H; ACTA Endocrinologica (Copenhagen) Suppl 1976, V82(202), P36 HCAPLUS
(3) Hersey, R; Endocrinology (Baltimore) 1982, V111(3), P896 HCAPLUS
(4) Kalyanaraman, B; Federation proceedings 1986, V45(10), P2477 HCAPLUS
(5) Kalyanaraman, B; Journal of Biological Chemistry 1984, V259(22), P14018 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L81 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:21628 HCAPLUS
DN 130:78449
TI Method of detecting estrogen-sensitive pathologies by determining levels of estrone metabolites and their glucuronide conjugates
IN Klug, Thomas L.
PA Immuna Care Corporation, USA
SO U.S., 31 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
PI	US 5854009	A	19981229		US 1996-715406	19960918 <--
	US 5962242	A	19991005		US 1997-917650	19970822 <--
PRAI	US 1995-3966		19950919	<--		
	US 1996-715406		19960918	<--		

AB Diagnostic/prognostic methods are provided for screening for pathologies wherein an alteration in estrogen metab. is indicative of a pathol. or a susceptibility thereto. The methods comprise detecting and/or quantifying directly in tissues and body fluids of mammals abnormal levels of estrone metabolites and their glucuronide conjugates. Particularly preferred methods involve the use of the 16OHE1-, 2OHE1- or 2MeoE1-glucuronide fraction, i.e., the fraction which contains the metabolite and its 3-glucuronide conjugate. Methods of prepg. reagents to detect the 16OHE1-, 2OHE1-, and 2MeoE1-glucuronide fraction in tissues and body fluids are disclosed as well as test kits for performing the disclosed assays. Monoclonal antibodies were prepd. using estrone metabolite conjugates with keyhole limpet hemocyanin. The antibodies were characterized and used in ELISAs and immunohistochem. staining assays of normal and breast cancer sera and tissues.
IT **218918-07-1 218918-14-0**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(monoclonal antibody cross-reactivity to; method of detecting estrogen-sensitive pathologies by detg. levels of estrone metabolites and their glucuronide conjugates)
RN 218918-07-1 HCAPLUS
CN Estra-1,3,5(10)-triene-2,3,16,17-tetrol, (17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218918-14-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 25
RE
(1) Anon; EP 409176 1991 HCAPLUS
(3) Bradlow; Ann N Y Acad Sci 1995, V768, P180 HCAPLUS
(6) Fishman; Proc Natl Acad Sci USA 1980, V77, P4957 HCAPLUS
(7) Galbraith; N Engl J Med 1989, V321, P269 HCAPLUS
(11) Ikegawa; J Steroid Biochem 1983, V18, P329 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L81 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:297342 HCAPLUS
DN 126:274525
TI Method of cancer detection
IN Klug, Thomas L.
PA Immuna Care Corporation, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9711374	A1	19970327	WO 1996-US15096	19960919 <--
	W: AL, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2232380	AA	19970327	CA 1996-2232380	19960919 <--
	AU 9671146	A1	19970409	AU 1996-71146	19960919 <--
	EP 866969	A1	19980930	EP 1996-932288	19960919 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1995-3966		19950919 <--		

WO 1996-US15096 19960919 <--

AB Diagnostic/prognostic methods ar provided for screening for pathologies wherein an alteration metab. is indicative of a pathol. or a susceptibility thereto which comprise detecting and/or quantifying directly in tissues and body fluids of mammals abnormal levels of estrone metabolites and their glucuronide conjugates. Particularly preferred methods involve the use of the 16-hydroxyestrone, 2-hydroxyestrone, or 2-methoxyestrone glucuronide fractions, i.e., the fraction which contains the metabolite and its 3-glucuronide conjugate. Methods of prepg. reagents to detect said glucuronide fraction in tissues and body fluids are disclosed as well as test kits for performing the disclosed assays.

IT **547-81-9**, Epiestriol **1232-80-0**, 2-Hydroxyestriol **1236-72-2**, 2-Methoxyestriol **101534-28-5**, 4-Methoxyestriol
RL: ANT (Analyte); ANST (Analytical study)
(cancer detection by ELISA of estrone metabolite glucuronide fraction)

RN 547-81-9 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1232-80-0 HCAPLUS

CN Estra-1,3,5(10)-triene-2,3,16,17-tetrol, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1236-72-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, 2-methoxy-, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 101534-28-5 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 4-methoxy-, (16.alpha.,17.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:244398 HCAPLUS
DN 126:225448
TI Novel estrogens for treating autoimmune diseases
IN Brattsand, Ralph; Holmdahl, Rikard; Jansson, Liselotte; Loncar, Marjana; Pettersson, Lars
PA Astra Aktiebolag, Swed.; Brattsand, Ralph; Holmdahl, Rikard; Jansson, Liselotte; Loncar, Marjana; Pettersson, Lars
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9708188	A1	19970306	WO 1996-SE1028	19960820	<--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM					
	CA 2228803	AA	19970306	CA 1996-2228803	19960820	<--
	AU 9668405	A1	19970319	AU 1996-68405	19960820	<--
	EP 847399	A1	19980617	EP 1996-928771	19960820	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI					
	JP 11511457	T2	19991005	JP 1996-510174	19960820	<--
	US 6043236	A	20000328	US 1997-817683	19970423	<--
PRAI	SE 1995-2921		19950823	<--		
	WO 1996-SE1028		19960820	<--		

OS MARPAT 126:225448
GI



I

AB Estratrienes I [R = H, alkyl, cycloalkyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, protective group; R1, R2 = H, Me, Et, halogen; R3 = H, acyl, alkoxycarbonyl, aralkoxycarbonyl; R4 = H, Me, Et; Y = CH2, bond] were prepd. Thus, estrone was converted to its 3-dimethylthexyl ether which was treated with EtPPh3+ Br-, followed by SeO2-Me3COOH oxidn. and desilylation to give (17E)-3,16.alpha.-dihydroxy-19-norpregna-1,3,5(10),17(20)-tetraene. I show very low sex hormone side effects while retaining their antiinflammatory and immunosuppressant activity.

IT **188291-28-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of estratriene derivs. as inflammation inhibitors and immunosuppressants)

RN 188291-28-3 HCAPLUS
CN 19-Norpregna-1,3,5(10),20-tetraene-3,16-diol, (16.alpha.,17.xi.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:532227 HCAPLUS
DN 122:256433
TI Estrogens as antimitotic agents
IN D'Amato, Robert John; Folkman, Moses Judah
PA Children's Medical Center Corp., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9504535	A1	19950216	WO 1994-US8767	19940802 <--

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5504074	A	19960402	US 1993-102767	19930806	<--
CA 2168850	AA	19950216	CA 1994-2168850	19940802	<--
AU 9474509	A1	19950228	AU 1994-74509	19940802	<--
EP 713393	A1	19960529	EP 1994-924120	19940802	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 09501433	T2	19970210	JP 1994-506502	19940802	<--
US 5661143	A	19970826	US 1995-571265	19951212	<--
US 5892069	A	19990406	US 1997-838699	19970425	<--
PRAI US 1993-102767		19930806 <--			
WO 1994-US8767		19940802 <--			
US 1995-571265		19951212 <--			

OS MARPAT 122:256433

AB Drugs for treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivs., colchicine or combretastatin A-4 are described. The inhibition of tubulin polymn. by 2-methoxyestradiol (75 .mu.M) in a mixt. contg. monosodium glutamate, DMSO and MgCl2 was demonstrated.

IT **1236-72-2**, 2-MethoxyEstriol
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogens as antimitotic agents)

RN 1236-72-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, 2-methoxy-, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2001 ACS

AN 1995:520572 HCAPLUS

DN 122:282269

TI Steroids for prophylaxis and therapy of radical-mediated cell damage

IN Droescher, Peter; Menzenbach, Bernd; Ponsold, Kurt; Undeutsch, Bernd; Oettel, Michael; Roemer, wolfgang; Kaufmann, Guenter; Schroeder, Jens

PA Jenapharm GmbH, Germany

SO Ger., 6 pp.
CODEN: GWXXAW

DT **Patent**

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI DE 4338314	C1	19950330	DE 1993-4338314	19931110	<--
CA 2176370	AA	19950518	CA 1994-2176370	19941108	<--
WO 9513076	A1	19950518	WO 1994-DE1309	19941108	<--
W: AU, BG, BR, CA, CN, CZ, FI, HU, JP, KP, KR, LK, MN, NO, NZ, PL, RO, RU, SK, UA, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9481041	A1	19950529	AU 1994-81041	19941108	<--

	EP 728004	A1	19960828	EP 1995-900068	19941108 <--
	R: AT, BE, CH, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09507470	T2	19970729	JP 1994-513527	19941108 <--
	JP 2845625	B2	19990113		
	US 6172056	B1	20010109	US 1996-646341	19960509 <--
PRAI	DE 1993-4338314	A	19931110 <--		
	WO 1994-DE1309	W	19941108 <--		

AB Steroids with a phenolic A-ring structure are radical scavengers useful for prevention and treatment of radical-mediated cell damage. Not included are the known active compds. estradiol, estrone, estriol, their 2-hydroxy derivs., and steroids with cyclic substituents or with an amino group on the terminal C atom of an aliph. C-17 side chain. Particularly useful are compds. with an addnl. conjugated double bond or an 8(14) double bond. Thus, 8-dehydroestradiol inhibited lipid peroxidn. (IC50 1.0 .mu.M) and LDL peroxidn. in vitro and showed a binding affinity for uterine estrogen receptors 59.6% of that of 17.beta.-estradiol.

IT **162707-58-6**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steroids for prophylaxis and therapy of radical-mediated cell damage)

RN 162707-58-6 HCAPLUS

CN Estra-1,3,5(10),6-tetraene-3,16,17-triol, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2001 ACS

AN 1994:622993 HCAPLUS

DN 121:222993

TI Methods and formulations for use in treating oophorectomized women

IN Pike, Malcolm C.; Spicer, Darcy V.

PA University of Southern California, USA

SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.
CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340586	A	19940823	US 1993-62886	19930517 <--
	US 5211952	A	19930518	US 1991-684612	19910412 <--
	US 5340584	A	19940823	US 1993-952513	19930201 <--
	WO 9426208	A1	19941124	WO 1994-US5262	19940512 <--
	W: CA, FI, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 748191	A1	19961218	EP 1994-917357	19940512 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	NO 9504612	A	19960112	NO 1995-4612	19951115 <--
PRAI	US 1991-684612		19910412 <--		
	US 1993-952513		19930201 <--		
	WO 1992-US2973		19920410 <--		
	US 1993-62886		19930517 <--		
	WO 1994-US5262		19940512 <--		

AB Compns. and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amt. of an estrogenic compn. and an effective amt. of an androgenic compn. The levels of estrogens and androgens employed are sufficient to reduce bone mineral d. loss and minimize other side effects obsd. after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in addnl. side effects.

IT **50-50-0**, Estradiol benzoate **15183-37-6**, Estetrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

RN 50-50-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15183-37-6 HCAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, (15.alpha.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:622992 HCAPLUS
DN 121:222992
TI Method and formulations for use in treating benign gynecological disorders
IN Pike, Malcolm C.; Spicer, Darcy V.
PA University of Southern California, USA
SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 952,513.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340585	A	19940823	US 1993-62883	19930517 <--
	US 5211952	A	19930518	US 1991-684612	19910412 <--
	WO 9426207	A1	19941124	WO 1994-US5222	19940512 <--

CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15183-37-6 HCAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, (15.alpha.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:75884 HCAPLUS
DN 110:75884
TI Procedure for preparing steroid 16.alpha.,17.beta.-diols, useful as estrogens
IN Siebert, Jochen; Lahne, Christine; Pohnert, Walter
PA VEB Jenapharm, Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 253249	A1	19880113	DD 1986-295203	19861013 <--
	DD 253249	B1	19900328		

OS MARPAT 110:75884
GI



W: CA, FI, NO
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 748190 A1 19961218 EP 1994-917349 19940512 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
NO 9504611 A 19960116 NO 1995-4611 19951115 <--
PRAI US 1991-684612 19910412 <--
US 1992-952513 19921203 <--
US 1993-62883 19930517 <--
WO 1994-US5222 19940512 <--
AB Compns. and methods which are effective to treat benign gynecol. disorders for extended periods of time in women in whom the risk of endometrial stimulation is minimized or absent are described, wherein an effective amt. of a gonadotropin hormone-releasing hormone compn. and an effective amt. of an estrogenic compn. are provided over a period of time, optionally with addn. of an androgenic compn. For example, both buserelin and estradiol were provided in the form of microspheres prepd. from lactide-glycolide copolymer for i.m. administration over a 4 mo duration.
IT **50-50-0**, Estradiol benzoate **15183-37-6**, Estetrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH compn. and estrogenic compn. combination for treatment of benign gynecol. disorders)
RN 50-50-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15183-37-6 HCAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, (15.alpha.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:315832 HCAPLUS
DN 120:315832
TI Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
IN Serfontein, Willem J.
PA Vesta Medicines (Pty). Ltd., S. Afr.
SO U.S., 25 pp. Cont.-in-part of U.S. Ser. No. 125,996, abandoned.

CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 5254572	A	19931019		US 1990-466676	19900117	<--
	US 5631271	A	19970520		US 1993-100433	19930802	<--
PRAI	US 1987-125996		19871127	<--			
	US 1988-153973		19880209	<--			
	GB 1989-924		19890117	<--			
	US 1989-395033		19890817	<--			
	ZA 1986-4001		19861129	<--			
	US 1990-466676		19900117	<--			
	ZA 1992-6989		19920914	<--			

AB A method is disclosed for treatment or prophylaxis of depressed or inadequate intracellular pyridoxal phosphate levels in a human or animal patient resulting from a condition, wherein the pyridoxine (PN)-pyridoxal phosphate (PLP) pathway is disturbed or insufficient, either by chem. factors as occur in physiol. shock, myocardial infarction, release of polyamines or toxins by cell death or microbes, vitamin B6 antagonistic drugs; or by enzymic insufficiencies inherent in the cells of a patient caused by genetic lack of oxidase or genetic oxidase polymorphism; cellular immaturity of premature infants; in conditions involving anemia, destruction of erythrocytes (e.g. malaria, biliary fever). The deficiencies are counteracted by the administration of pyridoxal or a precursor of pyridoxal which in vivo, once it has entered the bloodstream, is rapidly converted into pyridoxal without the intervention of oxidase or oxygen, optionally and preferably without the intervention of kinase. Also provided are methods for diagnosing depressed or inadequate pyridoxal phosphate levels or disturbance in the PN-PLP pathway, for use in conjunction with the above treatment method. Dogs infected with Babesia canis were given std. treatment and pyridoxal.HCl infusion, control animals did not receive pyridoxal.HCl. Animals given the pyridoxal infusion responded much better to treatment than the controls. A kit and method to det. aspartate transaminase activity as a measure of the intracellular pyridoxal phosphate concn. is described. Formulation examples are given.

IT **65296-29-9 155408-41-6**
RL: BIOL (Biological study)
(estrogen tablets contg., pyridoxal in)
RN 65296-29-9 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.alpha.,17.beta.)-, mixt. with (17.beta.)-estra-1,3,5(10)-triene-3,17-diol (9CI) (CA INDEX NAME)

CM 1

CRN 50-28-2
CMF C18 H24 O2
CDES 4:17B.ESTR

Absolute stereochemistry.



CM 2

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



RN 155408-41-6 HCAPLUS
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)-, mixt. with (17.beta.)-estra-1,3,5(10)-triene-3,17-diol and (16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol (9CI) (CA INDEX NAME)

CM 1

CRN 68-22-4
CMF C20 H26 O2
CDES 4:17A.PREGN

Absolute stereochemistry.



CM 2

CRN 50-28-2
CMF C18 H24 O2
CDES 4:17B.ESTR

Absolute stereochemistry.



CM 3

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



L81 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1993:198196 HCAPLUS
DN 118:198196
TI Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
IN Spicer, Darcy Vernon; Pike, Malcolm Cecil
PA University of Southern California, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9218107	A1	19921029	WO 1992-US2973	19920410	<--
	W: CA, FI, NO, US					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE					
	US 5211952	A	19930518	US 1991-684612	19910412	<--
	CA 2084891	AA	19921013	CA 1992-2084891	19920410	<--
	CA 2084891	C	19990105			
	EP 538443	A1	19930428	EP 1992-910686	19920410	<--
	EP 538443	B1	19971001			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE					
	AT 158717	E	19971015	AT 1992-910686	19920410	<--
	ES 2109995	T3	19980201	ES 1992-910686	19920410	<--
	NO 9204755	A	19930209	NO 1992-4755	19921209	<--
	US 5340584	A	19940823	US 1993-952513	19930201	<--
PRAI	US 1991-684612		19910412	<--		
	WO 1992-US2973		19920410	<--		

AB Slow-release compns. for inhibiting conception and treating benign gynecol. disorders contain a gonadotropin hormone releasing hormone (GnRH), an estrogen to be released first, in addn. to a progestogen and, optionally, an androgen. An. i.m. delivery system for administration over 4 mo contains buserelin, estradiol, and progesterone, such that the amt. of GnRH is sufficient to suppress LH and FSH secretion during the entire period of administration. Both buserelin and estradiol are in the form of glycolide-lactide microspheres.

IT **50-50-0**, Estradiol benzoate **15183-37-6**, Estetrol **29130-44-7**
RL: BIOL (Biological study)
(contraceptive slow-release compns. contg. gonadotropin hormone releasing hormones and, as estrogen)

RN 50-50-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-benzoate (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 15183-37-6 HCAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, (15.alpha.,16.alpha.,17.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 29130-44-7 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, mono(hydrogen butanedioate),
(16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

CM 1

CRN 110-15-6
CMF C4 H6 O4

$HO_2C-CH_2-CH_2-CO_2H$

CM 2

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



L81 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:544371 HCAPLUS
DN 117:144371
TI Prophylactic and therapeutic agents for leukocytopenia containing catechol estrogens
IN Yagi, Kunio; Yukimura, Sadaaki
PA Zaidan Hojin Oyo Seikagaku Kenkyusho, Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04154723	A2	19920527	JP 1990-275218	19901016 <--
JP 2999539	B2	20000117		

AB The title antileukopenic agents contg. catechol estrogens as active ingredients are claimed. The agents is useful for treatment of leukocytopenia caused by tumor radiotherapy. Catechol estrogen was s.c. administered at 2 mg/kg to mice before and after .gamma.-ray irradn. (4 Gy), wt. of thymus, no. of leukocyte and lymphocyte 24 days after the irradn. were 38.8 mg, 2793, and 1695, vs. 24.5 mg, 1587, and 943, resp., for a control irradiated group given no drug and 40.7 mg, 3240, and 2564, resp., for an untreated control group. A tablet contg. catechol estrogen 10, cryst. cellulose 60, lactose 75, corn starch 60, and Mg stearate 5 mg was prepd.
IT **1232-80-0**, 2-Hydroxyestriol
RL: BIOL (Biological study)
(leukocytopenia inhibitors contg., in tumor radiotherapy)
RN 1232-80-0 HCAPLUS
CN Estra-1,3,5(10)-triene-2,3,16,17-tetrol, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 16 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:144147 HCAPLUS
DN 116:144147
TI Effects of a combined estrogen-gestagen regimen on serum levels of the

carboxy-terminal propeptide of human type I procollagen in osteoporosis
AU Hasling, Claus; Eriksen, Erik F.; Melkko, Jukka; Ristelli, Leila; Charles, Peder; Mosekilde, Leif; Risteli, Juha
CS Univ. Dep. Endocrinol., Aarhus Amtssygehus, Aarhus, Den.
SO J. Bone Miner. Res. (**1991**), 6(12), 1295-300
CODEN: JBMREJ; ISSN: 0884-0431
DT Journal
LA English
AB To test whether estrogen stimulates bone collagen prodn. in vivo, total-body type I collagen prodn. was measured in a group of 12 osteoporotic women undergoing cyclic therapy with a combined estrogen-gestagen prepn. over a period of 150 wk. The changes in collagen prodn., as reflected in serum levels of the carboxy-terminal propeptide of human type I procollagen (PICP), were correlated to changes in other markers of bone turnover and lumbar bone mineral content.
IT **66100-41-2**
RL: BIOL (Biological study)
(collagen formation by bone response to, in women, osteoporosis in relation to)
RN 66100-41-2 HCAPLUS
CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17.alpha.)-, mixt. with (17.beta.)-estra-1,3,5(10)-triene-3,17-diol and (16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol (9CI) (CA INDEX NAME)

CM 1

CRN 51-98-9
CMF C22 H28 O3
CDES 4:17A.PREGN

Absolute stereochemistry.



CM 2

CRN 50-28-2
CMF C18 H24 O2
CDES 4:17B.ESTR

Absolute stereochemistry.



CM 3

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



L81 ANSWER 17 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:648131 HCAPLUS
DN 115:248131
TI Lipid peroxide formation inhibitors containing catechol estrogens
IN Yagi, Kunio; Yukimura, Sadaaki
PA Applied Science Research Institute, Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03115222	A2	19910516	JP 1989-72167	19890324 <--
	JP 2835066	B2	19981214		

AB Lipid peroxide formation inhibitors contg. catechol estrogens as active ingredients are claimed. Catechol estrogens are useful for prevention and treatment of radiation damage, arteriosclerosis, and climacteric disorders assocd. with lipid peroxides. Mice were treated with 2-hydroxyestradiol (I) at 1 mg/kg s.c., irradiated with .gamma.-rays (1000 rad), and, after 3 h, treated with I. Lipid peroxides in serum and liver were 3.18 nmol/mL and 29.9 nmol/100 mg, resp., vs. 5.10 nmol/mL and 75.6 nmol/100 mg, resp., for a control without I treatment. A tablet contg. I 10, cryst. cellulose 60, lactose 75, corn starch 45, and Mg stearate 10 mg was prepd.
IT **1232-80-0**, 2-Hydroxyestriol
RL: BIOL (Biological study)
(lipid peroxide formation inhibition by)
RN 1232-80-0 HCAPLUS
CN Estra-1,3,5(10)-triene-2,3,16,17-tetrol, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 18 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:614850 HCAPLUS
DN 115:214850
TI Pharmaceutical composition for treatment of osteoporosis
IN Miura, Tomoshi; Aonuma, Shinichiro; Ohara, Hiroyuki
PA Nippon Zoki Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 424954	A1	19910502	EP 1990-120567	19901026 <--
	EP 424954	B1	19940427		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5116828	A	19920526	US 1990-603214	19901025 <--
	JP 03209328	A2	19910912	JP 1990-289657	19901026 <--
	JP 3113269	B2	20001127		
	AT 104854	E	19940515	AT 1990-120567	19901026 <--
	ES 2055845	T3	19940901	ES 1990-120567	19901026 <--
PRAI	JP 1989-281141	A	19891026 <--		
	EP 1990-120567	A	19901026 <--		

AB The title compn. comprises an estrogen and a thyroid hormone. By using the estrogen in combination with the thyroid hormone, a more increases in bone amt. can be obtained than in the case of administering the estrogen alone. Estradiol benzoate at 1 mg/kg/wk and L-thyroxine at 30 .mu.g/kg/day were administered to rats having exptl. induced osteoporosis and a bone d. in the femur was detd.; an increase (28%) in bone amt. was about twice higher than that of the group administered with the estrogen alone. Tablets contained estradiol 0.5, L-thyroxine 0.05, corn starch 40, and lactose to 250 mg/tablet.

IT **136974-78-2**
RL: BIOL (Biological study)
(osteoporosis treatment with)

RN 136974-78-2 HCAPLUS
CN L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, mixt. with (16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol (9CI) (CA INDEX NAME)

CM 1

CRN 51-48-9
CMF C15 H11 I4 N O4
CDES 5:L

Absolute stereochemistry.



CM 2

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



L81 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:442751 HCAPLUS
DN 115:42751
TI Method and materials for detecting pathology from alterations in estrogen metabolism
IN Michnovicz, Jon J.; Hershcopf, Richard J.; Bradlow, H. Leon; Fishman, Jack
PA Rockefeller University, USA
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409176	A2	19910123	EP 1990-113694	19900717 <--
	EP 409176	A3	19911030		
	EP 409176	B1	19990428		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 9059051	A1	19910117	AU 1990-59051	19900717 <--
	AU 641409	B2	19930923		
	CA 2021309	AA	19910118	CA 1990-2021309	19900717 <--
	JP 03215745	A2	19910920	JP 1990-190349	19900717 <--
	AT 179522	E	19990515	AT 1990-113694	19900717 <--
PRAI	US 1989-381064		19890717 <--		
	US 1990-549290		19900711 <--		

AB A method and assocd. materials for detecting pathol. by detg. alterations in estrogen metab. in mammals are disclosed which comprise isolating .gtoreq.2 distinct metabolites of estrone from a biol. sample taken from the mammal under examn., detg. the quantity of each of the metabolites in the sample, correlating the quantities of each metabolite with each other to arrive at a quotient of the metabolites, and comparing the quotient with an extrinsic quotient derived either previously from the mammal under test, as by the previous performance of the test, or from the testing of other subjects of the same species, to det. any alterations in the estrogen metab. from which such pathol., or pathologies, may be detected. Concns. of the estrone metabolites are measured by immunoassay, radioassay, receptor assay, or chromatog. anal. 2-Hydroxyestrone, 16.alpha.-hydroxyestrone, estrone, estradiol, and estriol in urine samples from smokers as well as nonsmokers were detd. by RIAs using 3H-labeled estrone or metabolites and antibodies to resp. estrone or metabolites. Urinary .alpha.-hydroxyestrone was significantly elevated in smokers compared with nonsmokers (17.2 vs. 9.4 .mu.g/g creatinine). A parallel redn. in urinary estriol was also obsd. in smokers (10.7 vs. 15.6 .mu.g/g creatinine). The ratio of 2-hydroxyestrone/estriol was 0.59 for nonsmokers but was 1.67 for smokers.

IT **547-81-9 15183-37-6**, 15.alpha.-Hydroxyestriol
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in urine or other body fluids, by RIA or other assay, for clin. diagnosis)

RN 547-81-9 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15183-37-6 HCAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, (15.alpha.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:75884 HCAPLUS
DN 110:75884
TI Procedure for preparing steroid 16.alpha.,17.beta.-diols, useful as estrogens
IN Siebert, Jochen; Lahne, Christine; Pohnert, Walter
PA VEB Jenapharm, Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 253249	A1	19880113	DD 1986-295203	19861013 <--
	DD 253249	B1	19900328		

OS MARPAT 110:75884
GI



AB A procedure for the prepn. of steroid 16.alpha.,17.beta.-diols by reductive ring cleavage was characterized in that steroid 16.alpha.,17.beta.-epoxy-17.beta.-acetates I (R1 = Me, Et; R2 = OH, OAc, OBz, O2CEt, OMe) are reacted with 0.3-1.5 mol dissolved alkali metal borohydride in the presence of an inorg. base and org. solvent or solvent mixt. at -10 to +50.degree. to give steroid 16.alpha.,17.beta.-diols II (R1 = Me, Et; R2 = OH, OMe), at the end of the reaction, the conversion interrupted by crystn. or pptn. 3-Benzoyloxy-17.beta.-acetoxy-16.alpha.,17.beta.-epoxy-1,3,5(10)-estratriene in CHCl3 was treated with MeOH, then with NaBH4 at 20-30.degree. dissolved in 2.0M NaOH. When addn. was complete H2SO4 was added to ppt. Na2SO4 and the mother liquor was concd. to ppt. estriol in 2 fractions of 90-92% purity and 99.0% total yield.

IT **19882-03-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as estrogen)

RN 19882-03-2 HCAPLUS

CN Gona-1,3,5(10)-triene-3,16,17-triol, 13-ethyl-, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 21 OF 32 HCAPLUS COPYRIGHT 2001 ACS

AN 1984:466822 HCAPLUS

DN 101:66822

TI Effect of 1,25-dihydroxyvitamin D3 on biochemical indexes of bone turnover in postmenopausal women

AU Tjellesen, L.; Christiansen, C.; Roedbro, P.

CS Dep. Clin. Chem., Glostrup Hosp., Glostrup, DK-2600, Den.

SO Acta Med. Scand. (**1984**), 215(5), 411-15
CODEN: AMSVAZ; ISSN: 0001-6101

DT Journal

LA English

AB Bone metab. was estd. by serum alk. phosphatase [9001-78-9] (index of bone formation) and fasting urinary excretions of Ca2+ and hydroxyproline [51-35-4] (indexes of bone resorption) in a group of early postmenopausal women and a group of 70-yr-old women, during 12 mo of treatment with 1,25-dihydroxycholecalciferol (1,25(OH)2D3) [32222-06-3], and compared to estrogen/gestagen treatment or placebo treatment. The groups treated with 1,25(OH)2D3 did not show any change in bone metab., neither in bone resorption nor in bone formation, during the treatment period when compared to the placebo group, whereas treatment with female hormones decreased both bone resorption and bone formation.

IT **66100-41-2**
RL: BIOL (Biological study)
(bone resorption response to, in postmenopausal women)

RN 66100-41-2 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17.alpha.)-, mixt. with (17.beta.)-estra-1,3,5(10)-triene-3,17-diol and (16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol (9CI) (CA INDEX NAME)

CM 1

CRN 51-98-9
CMF C22 H28 O3
CDES 4:17A.PREGN

Absolute stereochemistry.



CM 2

CRN 50-28-2
CMF C18 H24 O2
CDES 4:17B.ESTR

Absolute stereochemistry.



CM 3

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



L81 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1982:568926 HCAPLUS
DN 97:168926

TI Compositions inhibiting estrogen sulfotransferase activity
IN Brooks, Samuel C.
PA Wayne State University, USA
SO U.S., 11 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 4340602	A	19820720		US 1978-952592	19781018	<--
	US 4810700	A	19890307		US 1983-495221	19830518	<--
PRAI	US 1978-952592		19781018	<--			
	US 1982-355806		19820308	<--			

GI



II

AB estrogen sulfotransferase (I) [9032-76-2] inhibitor compns. (oral, vaginal or topical), consisting of II (R1 = Br, NO2 or H; R2 = Br, NO2, NH2 or H; R = H or C1-4 alkyl; R3 = O or H2; R4 = H2, O, or .alpha.-H and .beta.-OH) in admixts. with pharmaceutical carriers, are useful for the termination of pregnancy by preventing implantation of a blastocyst in the epithelial uterine lining of mammalian females. Thus, an ointment was prepd. contg. 2,4-dinitro-1,3,5-(10)-estratriene-3,17.beta.-diol (II, R1 = R2 = NO2, R = H, R3 = H2, R4 = .alpha.-H,.beta.-OH) [20823-11-4], liq. petrolatum 250, wool fat 200 and white petrolatum q.s. ad 1000 g. The I inhibitory activity of II was demonstrated. Estrogen metab. is discussed in relation II.

IT **50-50-0 547-81-9**
RL: BIOL (Biological study)
(estrogen sulfotransferase inhibition by)

RN 50-50-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 547-81-9 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1981:581518 HCAPLUS
DN 95:181518
TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis
AU Christiansen, C.; Christensen, M. S.; Rodbro, P.; Hagen, C.; Transbol, I.
CS Glostrup Hosp., Univ. Copenhagen, Glostrup, DK-2600, Den.
SO Eur. J. Clin. Invest. (**1981**), 11(4), 305-9
CODEN: EJCIB8; ISSN: 0014-2972
DT Journal
LA English
AB Treatment of postmenopausal women with the hormone replacement regimen Trisequens [**66100-41-2**] increased bone mineral content .apprx.1% during a 1-yr period. Treatment of the women with 1,25-dihydroxycholecalciferol [32222-06-3] alone in a daily dose of 0.25 .mu.g or combined with the hormone therapy had no effect on the rate of bone loss, and it caused a characteristic and pronounced increase in urinary Ca excretion. Thus, the vitamin D3 metabolite neither serves as an alternative nor as an additive to gonadal hormones in the prevention of postmenopausal osteoporosis.
IT **66100-41-2**
RL: BIOL (Biological study)
(osteoporosis prevention in response to vitamin D3 and, after menopause)
RN 66100-41-2 HCAPLUS
CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17.alpha.)-, mixt. with (17.beta.)-estra-1,3,5(10)-triene-3,17-diol and (16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol (9CI) (CA INDEX NAME)

CM 1

CRN 51-98-9
CMF C22 H28 O3
CDES 4:17A.PREGN

Absolute stereochemistry.



CM 2

CRN 50-28-2
CMF C18 H24 O2
CDES 4:17B.ESTR

Absolute stereochemistry.



CM 3

CRN 50-27-1
CMF C18 H24 O3
CDES 4:16A,17B.ESTR

Absolute stereochemistry.



L81 ANSWER 24 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1978:597804 HCAPLUS
DN 89:197804
TI Estradiol derivatives
IN Miki, Takakazu; Hiraga, Kentaro; Goto, Yoshikazu
PA Takeda Chemical Industries, Ltd., Japan
SO Japan. Kokai, 8 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 53065865	A2	19780612	JP 1976-140578	19761123 <--

GI



AB Fourteen estradiol derivs. I (R = alkyl; R1 = H, acyl) were prepd. by ether cleavage or deacylation of II (R2 = alkyl, acyl). I had antiestrogen activity (no data). Thus, a mixt. of 1 g 16.beta.-ethylestradiol 3-Me ether and 1.3 g pyridinium chloride was heated 2 h at 150.degree. to give 16.beta.-ethylestradiol.

IT **64272-42-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 64272-42-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, 16-butyl-, (16.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 25 OF 32 HCAPLUS COPYRIGHT 2001 ACS

AN 1977:584771 HCAPLUS

DN 87:184771

TI 16.beta.-Alkylestradiol derivatives

IN Miki, Takuichi; Hiraga, Kentaro; Goto, Giichi

PA Takeda Chemical Industries, Ltd., Japan

SO Ger. Offen., 24 pp.
CODEN: GWXXBX

DT **Patent**

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2653558	A1	19770608	DE 1976-2653558	19761125 <--
	JP 52065259	A2	19770530	JP 1975-142509	19751127 <--
	JP 61044878	B4	19861004		
	GB 1570597	A	19800702	GB 1976-49180	19761125 <--
	FR 2332999	A1	19770624	FR 1976-35824	19761126 <--
	FR 2332999	B1	19790406		
	CA 1076102	A1	19800422	CA 1976-266709	19761126 <--
	CH 629221	A	19820415	CH 1976-14943	19761126 <--
PRAI	JP 1975-142509		19751127 <--		

GI



I

AB Eight antiestrogenic 16.beta.-alkylestradiols I (R = Et, Me2CH, allyl, Bu, 3-butenyl; R1 = H, Ac, EtCO, PhCH2CH2CO, Bz) were prepd. routinely. Thus, 16.beta.-ethylestradiol 3-Me ether was heated with pyridine at 150.degree. to give I (R = Et, R1 = H), which was acetylated to the diacetate and then selectively hydrolyzed with K2CO3 in MeOH to I (R = Et, R1 = Ac).

IT **64272-42-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 64272-42-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, 16-butyl-, (16.beta.,17.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2001 ACS

AN 1976:519237 HCAPLUS

DN 85:119237

TI Radioimmunological determination of estrogens

IN Edwards, John Christopher; Hemesley, Paul

PA Radiochemical Centre Ltd., Engl..

SO Ger. Offen., 13 pp.
CODEN: GWXXBX

DT **Patent**

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2600465	A1	19760715	DE 1976-2600465	19760108 <--
	DE 2600465	B2	19810507		
	DE 2600465	C3	19821202		
PRAI	GB 1975-1012		19750109 <--		

AB Estradiol and other estrogens may be detd. by radioimmunol. procedures after labeling with radioiodine. Thus, Chloramine-T (0.5 mg/100 ml water) was mixed with estriol (50 .mu.g in 400 .mu.l EtOH) and Na125I (10 mCi/100 .mu.l dil. NaOH) for 5 min. Then, Na2S2O5 (1.2 mg/500 .mu.l water) was added followed in 5 min by 1 ml 0.1M HCl, and the mixt. was extd. with CHCl3. The extd. 125I-labeled estriol was purified by chromatog. and was used in the radioimmunol. detn. of estriol in biol. fluids. The latter procedure was improved by using an enzyme from Helix pomatia to split the estrogen from the proteins in the serum sample.

IT **15183-37-6**

RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in biol. fluids, by radioimmunoassay)
RN 15183-37-6 HCAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, (15.alpha.,16.alpha.,17.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 27 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1976:31310 HCAPLUS
DN 84:31310
TI Aromatic steroids
IN Gasc, Jean C.; Pierdet, Andre
PA Roussel-UCLAF, Fr.
SO Can., 21 pp.
CODEN: CAXXA4
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	CA 974227	A1	19750909	CA 1972-151317	19720908	<--
	FR 2152392	A1	19730427	FR 1971-32703	19710910	<--
	CH 556832	A	19741213	CH 1972-12557	19720824	<--
	IL 40251	A1	19761130	IL 1972-40251	19720829	<--
	US 3776902	A	19731204	US 1972-285885	19720901	<--
	BE 788500	A1	19730307	BE 1972-121762	19720907	<--
	ZA 7206138	A	19731031	ZA 1972-6138	19720907	<--
	NL 7212228	A	19730313	NL 1972-12228	19720908	<--
	JP 48034868	A2	19730522	JP 1972-89644	19720908	<--
	JP 51024511	B4	19760724			
	AU 7246469	A1	19740314	AU 1972-46469	19720908	<--
	GB 1407477	A	19750924	GB 1972-41880	19720908	<--
	GB 1407478	A	19750924	GB 1975-4251	19720908	<--
	SE 385903	B	19760726	SE 1972-11618	19720908	<--
	ES 406543	A1	19750916	ES 1972-406543	19720909	<--
	DK 131036	B	19750520	DK 1972-4472	19720911	<--
	CA 988509	A2	19760504	CA 1974-210610	19741002	<--
	JP 51101969	A2	19760908	JP 1976-10452	19760204	<--
	JP 56019880	B4	19810509			
PRAI	FR 1971-32703		19710910	<--		
	CA 1972-151317		19720908	<--		

GI For diagram(s), see printed CA Issue.
AB Estrogenic and uterotrophic (no data) norpregnatrienynetriols (R = H, Ac; R1 = HO, AcO, R2 = HC.tplbond.C, H; R1 = HC.tplbond.C, R2 = HO, AcO) were prepd. from I (R1R2 = O). Thus, I (R = H, R1R2 = O) was reduced with NaBH4 to give I (R1 = HO, R2 = H) and acetylated to I (R = Ac, R1R2 = O) (II). Ethynylation of II with HC.tplbond.CMgBr followed by sapon. gave I (R = H, R1 = HO, R2 = C.tplbond.CH and R = H, R1 = C.tplbond.CH, R2 = HO).
IT **41142-59-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 41142-59-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, 11-methoxy-,
(11.beta.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1973:537384 HCAPLUS
DN 79:137384
TI Highly active estratriols
IN Anner, Georg; Kalvoda, Jaroslav
PA Civa-Geigy A.-G.
SO Swiss, 3 pp.
CODEN: SWXXAS
DT **Patent**
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 538460	A	19730815	CH 1973-3101	19690227 <--

GI For diagram(s), see printed CA Issue.
AB Estratrienetriol I (R = R3 = H; R1 = R2 = OH) (II) was prepd. from 7.alpha.-methylestrone (I, RR1 = O, R2 = R3 = H). Thus, I (RR1 = O, R2 = R3 = H) was treated with CH2:C(OAc)Me and the product III was epoxidized to I (R = H, R1R2 = O, R3 = Ac). LiAlH4 redn. of the latter and subsequent hydrolysis gave II. II had estrogenic activity in Allen-Doisy test of 0.001-0.1 mg/kg s.c. and 0.02-0.3 mg/kg orally in rats, and in Buelbring-Buen test of 0.0003-0.003 mg/kg s.c. and 0.003-0.03 mg/kg orally in rats. II had antigonadotropic activity of 0.0003-0.003 mg/kg s.c. or 0.003-0.01 mg/kg orally in Parabiosis test. Also, II inhibited ovulation and embryo implantation.
IT **28834-40-4P**
RL: BAC (Biological activity or effector, except adverse); IMF (Industrial manufacture); BIOL (Biological study); PREP (Preparation)
(manuf. and biol. activity of)
RN 28834-40-4 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 7-methyl-,
(7.alpha.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 29 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1973:537383 HCAPLUS
DN 79:137383
TI Estratriols
IN Anner, Georg; Kalvoda, Jaroslav
PA Ciba-Geigy A.-G.
SO Swiss, 3 pp. Division of Swiss 537,915 (See Ger. 2,007,415, CA 73;109980c).
CODEN: SWXXAS
DT **Patent**
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 537916	A	19730731	CH 1973-2813	19690227 <--

GI For diagram(s), see printed CA Issue.
AB Estratriol I (R = OH, R1 = H, R2 = OH) (II) was prepd. from 7.alpha.-methylestrone I (RR1 = O, R2 = H), in 3 steps. Thus, I (RR1 = O, R2 = H) was treated with CH2:CMeOAc and the resulting enol acetate was reacted with m-ClC6H4CO2OH. The epoxide I (R = OH, R1R2 = O) diacetate was LiAlH4 reduced to II. II had estrogenic activity of 0.003-0.3 mg/kg s.c. and 0.01-3 mg/kg orally in Allen Doisy Test and 0.003-0.3 mg/kg s.c. and 0.003-1 mg/kg orally in Buelbring-Buen test. Also, II had antigonadotropic activity of 0.003-0.03 mg/kg s.c., and 0.01-0.3 mg/kg orally and inhibited ovulation at 0.0001-0.003 mg/kg s.c. and 0.003-0.1 mg/kg orally.
IT **28838-18-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 28838-18-8 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 7-methyl-, (7.alpha.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1972:568615 HCAPLUS
DN 77:168615
TI Menopausal hormone compositions
IN Desaulles, Pierre A.; Hunger, Alfred; Bein, Hugo J.
PA Ciba-Geigy A.-G.
SO Ger. Offen., 21 pp.
CODEN: GWXXBX
DT **Patent**
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2209244	A	19720921	DE 1972-2209244	19720226 <--
ZA 7201169	A	19721129	ZA 1972-1169	19720222 <--
BE 780172	A1	19720904	BE 1972-114642	19720303 <--
NL 7202873	A	19720907	NL 1972-2873	19720303 <--
FR 2128593	A5	19721020	FR 1972-7489	19720303 <--

PRAI CH 1971-3234 19710305 <--
AB Formulations contg. tranquilizing 9-(methylaminomethyl)-9,10-dihydro-9, 10-ethanoanthracene (I) in addn. to an estrogen, useful against climacteric irritations, were described. A typical tablet contained I 5.0, 7.alpha.-methylestrone 0.2, lactose 88.0, wheat starch 45.8, colloidal silicic acid 5.0, talc 5.0, and Mg stearate 1.0 mg.
IT **28834-40-4**
RL: BIOL (Biological study)
(pharmaceutical, for menopause disorder treatment)
RN 28834-40-4 HCAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 7-methyl-, (7.alpha.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1972:49943 HCAPLUS
DN 76:49943
TI Inducing ovulation with compositions comprising 13-alkyl-16.alpha.-hydroxy-3,17-dioxygenated-gona-1,3,5(10)-trienes
IN Edgren, Richard A.
PA American Home Products Corp.
SO U.S., 5 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3622670	A	19711123	US 1969-852447	19690822 <--

GI For diagram(s), see printed CA Issue.
AB 13-Ethylgona-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol (I) and a carrier were used to induce ovulation in warm-blooded anovulatory vertebrates after administration. I was prepd. by LiAlH4 redn. of 3,17-diacetoxy-16.alpha.,17.alpha.-epoxy-1,3,5(10)-triene (II) followed by treatment with EtOAc and 2N HCl. In an example, tablets were prepd. from I 5, CM-cellulose 15, lactose 25, redried corn starch 25, Mg stearate 4 mg, and sufficient Ca silicate to give 200 mg of tablet.
IT **19882-03-2 36292-12-3**
RL: BIOL (Biological study)
(for ovulation induction)
RN 19882-03-2 HCAPLUS
CN Gona-1,3,5(10)-triene-3,16,17-triol, 13-ethyl-, (16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36292-12-3 HCAPLUS
CN Gona-1,3,5(10)-triene-3,11,16,17-tetrol, 13-ethyl-, (11.alpha.,16.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L81 ANSWER 32 OF 32 HCAPLUS COPYRIGHT 2001 ACS
AN 1970:469865 HCAPLUS
DN 73:69865
TI Poly(estriol phosphate)-based pharmaceutical compositions for treatment of menopause symptoms
IN Ferno, Ove B.; Fex, Hans J.; Hogberg, Knut B.; Konyves, Imre; Linderot, Torsten O. E.
PA Aktiebolag Leo
SO Fr. Demande, 6 pp.
CODEN: FRXXBL
DT **Patent**
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2000281	A1	19690905	FR 1969-505	19690115 <--
PRAI US 1968-698152		19680116 <--		

AB Menopause symptoms were treated without severe depressive side-effects by an injectable, preferably lyophilized, compn. of pH 6.3-7.5, contg. 2 5 wt.% of the title compd. (I) (cf. U.S. 2,928,849), .ltoreq.4% of a local anesthetic (e.g. mepivacaine) and 12% of a solubilizing agent (e.g. nicotinamide). Preferred dosage is 1-5 ml (20-100 mg I) effective for 1-2 months, and repeatable over 5 years. Thus, a mixt. of I 800, NaOH 57, nicotinamide 660, mepivacaine 50, Na3PO4 20 g, and distd. H2O to 101. was adjusted to pH 7.1, filled into 1 ml ampuls, and freeze-dried.
IT **31117-33-6**
RL: BIOL (Biological study)
(pharmaceuticals, for menopause therapy)
RN 31117-33-6 HCAPLUS

=> fil reg
FILE 'REGISTRY' ENTERED AT 13:42:44 ON 31 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

STRUCTURE FILE UPDATES: 29 OCT 2001 HIGHEST RN 365398-80-7
DICTIONARY FILE UPDATES: 29 OCT 2001 HIGHEST RN 365398-80-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER see HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s 31117-33-6
L82 1 31117-33-6
(31117-33-6/RN)

=> d ide can

L82 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 37452-43-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,16,17-triol, (16.alpha.,17.beta.)-, polymer with phosphoric acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estriol, polyester with phosphoric acid (8CI)
CN Phosphoric acid, polyester with estriol (8CI)
CN Phosphoric acid, polymer with (16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol (9CI)
OTHER NAMES:
CN Poly(estriol phosphate)
CN Triodurin
FS STEREOSEARCH
DR **31117-33-6**
MF (C18 H24 O3 . H3 O4 P)x
CI PMS
PCT Polyother, Polyother only
LC STN Files: BIOSIS, CA, CAPLUS, EMBASE, TOXLIT

CM 1

CRN 7664-38-2
CMF H3 O4 P



CM 2

CRN 50-27-1
CMF C18 H24 O3

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 77:70535

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:42:55 ON 31 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 31 Oct 2001 VOL 135 ISS 19
FILE LAST UPDATED: 30 Oct 2001 (20011030/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d l78 bib abs hitrn

L78 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:552017 HCAPLUS
DN 133:150782
TI synthesis of 16-Hydroxyestratrienes as selectively effective estrogens
IN **Kuenzer, Hermann; Knauthe, Rudolf; Lessl, Monika; Fritzemeier, Karl-heinrich; Hegele-Hartung, Christa; Boemer, Ulf; Mueller, Gerd; Kosemund, Dirk**
PA Schering A.-G., Germany
SO Ger. Offen., 34 pp.
CODEN: GWXXBX
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19906159	A1	20000810	DE 1999-19906159	19990209 <--

WO 2000047603 A2 20000817 WO 2000-EP1073 20000209 <--
WO 2000047603 A3 20010802
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2000029095 A5 20000829 AU 2000-29095 20000209 <--
EP 1144431 A2 20011017 EP 2000-907539 20000209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRAI DE 1999-19906159 A 19990209 <--
WO 2000-EP1073 W 20000209
OS MARPAT 133:150782
GI



I

AB Synthesis of 16-Hydroxyestratrienes (I) [R1 = halogen, HO, Me, F3C, MeO, EtO, H; R2 = halogen, HO, (un)substituted alkoxy, H; R4 = halogen, fluoroalkyl, F3C, F5C2, (un)substituted alkoxy, H; R7 = halogen, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkoxy, (un)substituted heteroaryl, (un)substituted aryl, H; R8 = H, fluoroalkyl, fluoroalkenyl, CN; R9 = H, Me, Et, F3C, F5C2; R11 = NO2O, HO, HS, halogen, chloromethyl, fluoroalkenyl, fluoroalkyl, (un)substituted alkoxy, (un)substituted alkylthio, (un)substituted aryl, (un)substituted heteroaryl, H; R13 = Me, Et, F3C, F5C2; R14 = (un)substituted alkenyl, (un)substituted alkyl, H; R15 = halogen, fluoroalkyl, fluoroalkenyl, =O, =S, SO, SO2, (un)substituted =NH; R14, R15 together = methylene; R16 = fluoroalkyl, fluoroalkenyl, F3C, F5C2,CN, H; R17 = fluoroalkyl, fluoroalkenyl, H, HO] as selectively effective estrogens is disclosed. Thus, 16.alpha.-estradiol shows a 50% uterine stimulation at 30 .upsilon.g in in vivo testing.

IT **287721-55-5P 287721-56-6P 287721-57-7P**
287721-58-8P 287721-59-9P 287721-60-2P
287721-61-3P 287721-62-4P 287721-63-5P
287721-64-6P 287721-66-8P 287721-67-9P
287721-71-5P 287721-72-6P 287721-73-7P
287721-74-8P 287721-75-9P 287721-77-1P
287721-80-6P 287721-81-7P 287721-85-1P
287721-86-2P 287721-87-3P 287721-88-4P
287721-90-8P 287721-93-1P 287721-94-2P
287721-95-3P 287721-96-4P 287721-97-5P
287721-98-6P 287722-01-4P 287722-02-5P
287722-03-6P 287722-04-7P 287722-05-8P
287722-06-9P 287722-09-2P 287722-10-5P
287722-11-6P 287722-12-7P 287722-13-8P
287722-14-9P 287722-17-2P 287722-18-3P

287722-19-4P 287722-20-7P 287722-21-8P
287722-22-9P 287722-25-2P 287722-26-3P
287722-27-4P 287722-28-5P 287722-29-6P
287722-30-9P 287722-31-0P 287722-32-1P
287722-33-2P 287722-34-3P 287722-35-4P
287722-36-5P 287722-37-6P 287722-38-7P
287722-39-8P 287722-40-1P 287722-41-2P
287722-42-3P 287722-43-4P 287722-44-5P
287722-45-6P 287722-46-7P 287722-47-8P
287722-48-9P 287722-49-0P 287722-50-3P
287722-51-4P 287722-52-5P 287722-53-6P
287722-54-7P 287722-55-8P 287722-56-9P
287722-57-0P 287722-58-1P 287722-59-2P
287722-60-5P 287722-61-6P 287722-62-7P
287722-63-8P 287722-64-9P 287722-67-2P
287722-68-3P 287722-69-4P 287722-70-7P
287722-71-8P 287722-72-9P 287722-75-2P
287722-76-3P 287722-77-4P 287722-78-5P
287722-79-6P 287722-80-9P 287722-83-2P
287722-84-3P 287722-85-4P 287722-86-5P
287722-87-6P 287722-88-7P 287722-91-2P
287722-92-3P 287722-93-4P 287722-94-5P
287722-95-6P 287722-96-7P 287722-97-8P
287722-98-9P 287722-99-0P 287723-00-6P
287723-01-7P 287723-02-8P 287723-03-9P
287723-04-0P 287723-05-1P 287723-06-2P
287723-07-3P 287723-08-4P 287723-09-5P
287723-10-8P 287723-11-9P 287723-12-0P
287723-13-1P 287723-14-2P 287723-15-3P
287723-16-4P 287723-17-5P 287723-18-6P
287723-19-7P 287723-20-0P 287723-21-1P
287723-22-2P 287723-23-3P 287723-24-4P
287723-29-9P 287723-30-2P 287723-31-3P
287723-32-4P 287723-33-5P 287723-37-9P
287723-42-6P 287723-43-7P 287723-48-2P
287723-49-3P 287723-50-6P 287723-51-7P
287723-53-9P 287723-56-2P 287723-57-3P
287723-58-4P 287723-59-5P 287723-60-8P
287723-61-9P 287723-62-0P 287723-63-1P
287723-64-2P 287723-65-3P 287723-66-4P
287723-67-5P 287723-68-6P 287723-69-7P
287723-70-0P 287723-71-1P 287723-72-2P
287723-73-3P 287723-75-5P 287723-77-7P
287723-79-9P 287723-80-2P 287723-81-3P
287723-82-4P 287723-83-5P 287723-84-6P
287723-85-7P 287723-86-8P 287723-87-9P
287723-88-0P 287723-89-1P 287723-90-4P
287723-91-5P 287723-92-6P 287723-93-7P
287723-94-8P 287723-95-9P 287723-96-0P
287723-97-1P 287723-98-2P 287723-99-3P
287724-00-9P 287724-01-0P 287724-02-1P
287724-03-2P 287724-04-3P 287724-05-4P
287724-06-5P 287724-07-6P 287724-08-7P
287724-09-8P 287724-10-1P 287724-11-2P
287724-12-3P 287724-13-4P 287724-14-5P
287724-15-6P 287724-16-7P 287724-17-8P
287724-18-9P 287724-19-0P 287724-20-3P
287724-21-4P 287724-22-5P 287724-23-6P
287724-24-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of 16-Hydroxyestratrienes as selectively effective estrogens)

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:43:22 ON 31 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 31 Oct 2001  VOL 135 ISS 19
FILE LAST UPDATED: 30 Oct 2001  (20011030/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REG1stRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

HCAplus now provides online access to patents and literature covered
in CA from 1947 to the present.  On April 22, 2001, bibliographic
information and abstracts were added for over 2.2 million references
published in CA from 1947 to 1966.


=> fil reg
FILE 'REGISTRY' ENTERED AT 14:03:47 ON 31 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   29 OCT 2001  HIGHEST RN 365398-80-7
DICTIONARY FILE UPDATES:  29 OCT 2001  HIGHEST RN 365398-80-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER see
HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sca l98

L98  265 ANSWERS   REGISTRY  COPYRIGHT 2001 ACS
IN   Estra-1,3,5(10)-triene-3,16-diol, 11-fluoro-15-(1-methylethyl)-,
     (11.beta.,15.beta.,16.beta.)- (9CI)
MF   C21 H29 F O2

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 7-propyl-, (7.beta.,16.beta.)- (9CI)
MF C21 H30 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 15-methoxy-7-phenyl-,
(7.alpha.,15.beta.,16.beta.)- (9CI)
MF C25 H30 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 11-fluoro-7-(methylthio)-,
(7.alpha.,11.beta.,16.beta.)- (9CI)

MF C19 H25 F O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Cycloprop[14,15]estra-1,3,5(10)-triene-3,16-diol, 3',15-dihydro-, (14R,15.beta.,16.beta.)- (9CI)
MF C19 H24 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 11-methoxy-7-phenyl-, (7.alpha.,11.beta.,16.beta.)- (9CI)
MF C25 H30 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 15-propyl-, (15.beta.,16.alpha.)- (9CI)
MF C21 H30 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 11-fluoro-15-(methylthio)-7-phenyl-, (7.alpha.,11.beta.,15.beta.,16.alpha.)- (9CI)
MF C25 H29 F O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 11-fluoro-15-(methylthio)-, (11.beta.,15.alpha.,16.beta.)- (9CI)
MF C19 H25 F O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 7-phenyl-, (7.beta.,16.alpha.)- (9CI)
MF C24 H28 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L98 265 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Estra-1,3,5(10)-triene-3,16-diol, 15-ethyl-7-phenyl-, (7.alpha.,15.beta.,16.alpha.)- (9CI)
MF C26 H32 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 12:22:57 ON 31 OCT 2001)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:23:08 ON 31 OCT 2001
L1 229680 S C5-C6-C6-C6/ES
L2 538 S L1 AND C20H28O2
L3 526 S L2 AND 1/NC

FILE 'HCAPLUS' ENTERED AT 12:24:46 ON 31 OCT 2001
E FRITZEMEIER K/AU
L4 60 S E4-E8
E KUENZER H/AU
L5 50 S E3,E5
E KUNZER H/AU
L6 10 S E3,E4
E KNAUTHE R/AU
L7 13 S E3,E5
E LESSL M/AU
L8 23 S E3,E4
E HEGELE/AU
L9 51 S E8-E10
E HARTUNG/AU
L10 13 S E3,E16

```
                E BOEMER U/AU
L11           6 S E4
                E BOMER U/AU
L12           7 S E4
                E MUELLER G/AU
L13        1016 S E3-E22
L14         148 S E64-E67
                E MULLER G/AU
L15         463 S E3-E17,E36-E39
                E KOSEMUND D/AU
L16           7 S E3,E4
                E DE99-19906159/AP,PRN
L17           1 S E3,E4
L18           1 S L17 AND L4-L16
L19          87 S STEROID?/SC,SX,CW AND L4-L16
L20          86 S L19 NOT L18
                SEL RN L18

    FILE 'REGISTRY' ENTERED AT 12:28:45 ON 31 OCT 2001
L21         289 S E1-E289
L22          10 S L21 AND L2
L23         491 S 4432.3/RID AND L2
L24         144 S L23 AND 4432.3.65/RID
L25          13 S L24 AND 13 ETHYL
L26           3 S L25 NOT METHOXY
L27          24 S L23 AND 13 ETHYL NOT METHOXY
L28          21 S L27 NOT L25
L29             STR
L30          12 S L29 CSS
L31         425 S L29 CSS FUL
                SAV TEMP L31 QAZI497/A
L32             STR L29
L33         400 S L32 CSS FUL SUB=L31
                SAV TEMP L33 QAZI497A/A
L34          12 S L33 AND C3-C5-C6-C6-C6/ES
L35         388 S L33 NOT L34
L36             STR L32
L37         385 S L36 CSS FUL SUB=L35
                SAV L37 QAZI497B/A
L38           3 S L35 NOT L37
L39           1 S L38 AND C18H22O3
L40         398 S L34,L37,L39
                SAV L40 TEMP QAZI497C/A

    FILE 'REGISTRY' ENTERED AT 13:19:22 ON 31 OCT 2001
L41           8 S L40 AND C20H28O2

    FILE 'HCAPLUS' ENTERED AT 13:20:08 ON 31 OCT 2001
L42        4261 S L40
L43           4 S L42 AND L4-L18

    FILE 'REGISTRY' ENTERED AT 13:21:16 ON 31 OCT 2001
L44           1 S ESTRIOL/CN
                E ESTRA-1,3,5(10)-TRIENE-3,16/CN
                E ESTRA-1,3,5(10)-TRIENE-3,16-DIOL/CN
L45           2 S E4,E5
                E ESTRA-1,3,5(10),7-TETRAENE-3,16-DIOL/CN
                E ESTRA-1,3,5(10),7-TETRAEN/CN
                E ESTRA-1,3,5(10),7-TETRAENE/CN
L46           1 S E28
                E RSD
L47         245 S 4432.3.177/RID
L48          15 S C18H22O2 AND L47
L49           4 S L48 AND 16
L50           2 S L49 NOT D/ELS
L51           4 S L45,L50
```

```
L52          395 S L40 NOT L44,L51

     FILE 'HCAPLUS' ENTERED AT 13:30:49 ON 31 OCT 2001
L53          654 S L52
L54          628 S L53 AND (PD<=19990427 OR PRD<=19990427 OR AD<=19990427)
L55            1 S L4-L18 AND L53
                 E ESTROGEN/CW
L56        34431 S E3-E5
                 E ESTROGEN/CT
                 E E5+ALL
L57          130 S E1
                 E E2+ALL
L58          271 S E7
                 E E6+ALL
L59        33010 S E6,E7,E21-E25
L60         6077 S E27+NT
L61         1703 S E28+NT
L62        36014 S E29+NT
                 E E27+ALL
L63         6728 S E14
                 E OVARY/CT
                 E E3+ALL
L64        37307 S E7,E6+NT
L65        24849 S E17+NT
L66         8203 S E20+NT
                 E E19+ALL
L67         8806 S E4,E3+NT
L68          953 S E13+NT
                 E E12+ALL
L69         1703 S E4+NT
                 E E10+ALL
L70         5444 S E5,E4+NT
L71          273 S L54 AND L56-L70
                 E OSTEOPOR/CT
                 E E4+ALL
L72         6222 S E6+NT
                 E BONE DENSITY/CT
L73          743 S E4
L74          268 S E2
L75            6 S L54 AND L72-L74
L76           30 S L71 AND P/DT
L77           33 S L75,L76
L78            1 S L77 AND L55
L79           32 S L77 NOT L78
                 SEL HIT RN L79

     FILE 'REGISTRY' ENTERED AT 13:38:36 ON 31 OCT 2001
L80           26 S E1-E26

     FILE 'HCAPLUS' ENTERED AT 13:41:35 ON 31 OCT 2001
L81           32 S L80 AND L79

     FILE 'REGISTRY' ENTERED AT 13:42:44 ON 31 OCT 2001
L82            1 S 31117-33-6

     FILE 'HCAPLUS' ENTERED AT 13:42:55 ON 31 OCT 2001

     FILE 'HCAPLUS' ENTERED AT 13:43:22 ON 31 OCT 2001

     FILE 'REGISTRY' ENTERED AT 13:43:55 ON 31 OCT 2001
L83          265 S L1 AND L21
L84           24 S L21 AND C3-C5-C6-C6-C6/ES
L85           24 S L84 NOT L30
L86          289 S L83,L85
L87           56 S L83 NOT L40
L88           20 S L87 AND (C26H32N2O3S OR C19H24O2 OR C19H25BRO2 OR C23H28O4 OR
```

```
L89           6 S L87 AND (C20H26O2 OR C20H27BRO2 OR C20H26O OR C20H26O2 OR C20
L90          26 S L88,L89
L91           4 S L90 AND C19H24O2
L92           3 S L91 NOT 13865-88-8
L93          23 S L90 NOT L92
L94          33 S L87 NOT L93
L95         266 S L86 NOT L93
                SAV L95 TEMP QAZI497D/A

     FILE 'HCAPLUS' ENTERED AT 14:01:54 ON 31 OCT 2001
L96          12 S L95

     FILE 'REGISTRY' ENTERED AT 14:02:58 ON 31 OCT 2001
L97           1 S 1225-58-7
L98         265 S L95 NOT L97

     FILE 'HCAPLUS' ENTERED AT 14:03:32 ON 31 OCT 2001
L99           1 S L98

     FILE 'USPATFULL' ENTERED AT 14:03:36 ON 31 OCT 2001
L100          0 S L98

     FILE 'REGISTRY' ENTERED AT 14:03:47 ON 31 OCT 2001
```